| Group I | Group II | Group III | Group IV | Group V | Group VI |
---|---|---|---|---|---|---|
negative control | cisplatin ‘CDDP’-treated | cisplatin + rBMSCs-treated | cisplatin + hADSCs-treated | cisplatin + hAFSCs-treated | cisplatin + DMEM culture media-treated | |
Sr. Cr. (mg/dL) | ||||||
 Day 4 | 0.40 ± 0.12 | 1.92 ± 0.03a | 0.92 ± 0.05ab | 0.97 ± 0.02ab | 1.02 ± 0.08ab | 1.88 ± 0.10acde |
 Day 7 | 0.37 ± 0.12 | 1.61 ± 0.05a | 0.79 ± 0.04ab | 0.87 ± 0.06ab | 0.85 ± 0.07ab | 1.63 ± 0.03acde |
 Day 11 | 0.40 ± 0.11 | 1.00 ± 0.07a | 0.67 ± 0.1ab | 0.72 ± 0.05ab | 0.70 ± 0.06ab | 1.02 ± 0.10acde |
 Day 30 | 0.39 ± 0.10 | 0.77 ± 0.03 a | 0.52 ± 0.06ab | 0.58 ± 0.06ab | 0.58 ± 0.05ab | 0.81 ± 0.04acde |
BUN (mg/dL) | ||||||
 Day 4 | 18.6 ± 1.14 | 85.6 ± 1.67a | 32.0 ± 1.58ab | 30.2 ± 0.83ab | 34.4 ± 1.14ab | 85.4 ± 1.14acde |
 Day 7 | 18.2 ± 1.48 | 55.2 ± 1.30a | 27.2 ± 1.30ab | 27.8 ± 1.30ab | 28.0 ± 1.22ab | 53.8 ± 0.84acde |
 Day 11 | 17.2 ± 1.48 | 32.3 ± 1.48a | 24.2 ± 0.83ab | 24.2 ± 1.30ab | 24.4 ± 0.89ab | 32.4 ± 1.51acde |
 Day 30 | 18.0 ± 1.58 | 26.4 ± 0.55a | 22.2 ± 0.83ab | 22.4 ± 0.89ab | 23.2 ± 0.84ab | 26.2 ± 0.83acde |
Cr. Cl. (mL/min/100 gm) | ||||||
 Day 4 | 1.62 ± 0.44 | 0.007 ± 0.001a | 0.021 ± 0.005a | 0.021 ± 0.006a | 0.018 ± 0.006a | 0.008 ± 0.001a |
 Day 7 | 1.78 ± 0.55 | 0.014 ± 0.001a | 0.052 ± 0.008a | 0.048 ± 0.001a | 0.045 ± 0.001a | 0.012 ± 0.002a |
 Day 11 | 1.86 ± 0.56 | 0.05 ± 0.01a | 0.07 ± 0.01a | 0.06 ± 0.01a | 0.06 ± 0.007a | 0.05 ± 0.013a |
 Day 30 | 1.76 ± 0.55 | 0.36 ± 0.17a | 0.92 ± 0.23a | 0.89 ± 0.15a | 1.00 ± 0.14ab | 0.46 ± 0.26a |